Comparison of the adjuvanticity of aluminum salts and their combination in hepatitis B recombinant protein vaccine in assessed mice

Iranian Journal of Immunology

Volumn 5, Issue 3, 2008, Pages 163-170

  Mahboubi, Arash ^a   Fazeli, Mohammad Reza ^a   Dinarvand, Rasoul ^a,b   Samadi, Nasrin ^a,f   Sharifzadeh, Mohammad ^b   Ilka, Houshmand ^c   Azadi, Saeed ^d   Soleimanian, Roya ^d   Kalkouei, Hassan ^d   Hajikhanmirzaei, Rasoul ^d   Valadkhani, Mahboubeh ^e  

^a Department of Pharmaceutics ^*  (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c Zist Daru Danesh Ltd   (Iran)

^d Biotechnology Department of Darou Pakhsh Pharmaceutical Mfg Co   (Iran)

^e MINISTRY OF HEALTH AND MEDICAL EDUCATION   (Iran)

^f TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Aluminum; BALB c mice; Hepatitis B vaccine

Indexed keywords

ADJU PHOS; ALUMINUM HYDROXIDE; ALUMINUM PHOSPHATE; HEPATITIS B VACCINE; RECOMBINANT HEPATITIS B VACCINE; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ANIMAL EXPERIMENT; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; MOUSE; NONHUMAN; SEROCONVERSION;

EID: 50949123659     PISSN: 17351383     EISSN: 1735367X     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Jones LS, Peek LJ, Power J, Markham A, Yazzie B, Middaugh CR. Effects of adsorption to aluminum salt adjuvants on the structure and stability of model protein antigens. J Biol Chem. 2005;280:13406-14.
2. Hunter RL. Overview of vaccine adjuvants: present and future. Vaccine. 2002; 20: S7-12.
3. Lindblad EB. Aluminium compounds for use in vaccines. Immunol Cell Biol. 2004; 82: 497-505.
4. Vogel R, Powell MF. A compendium of vaccine adjuvants and excipients. Pharm Biotechnol.1995; 6: 141-228.
5. Gupta RK, Siber GR Adjuvants for human vaccine- current status, problems and feature prospects. Vaccine. 1995; 13: 1263-76.
6. Hem SL, White JL. Structure and properties of aluminum-containing adjuvants. Pharm Biotechnol.1995; 6: 249-76.
7. Baylor NW, Egan W, Richman P. Aluminum salts in vaccines - US perspective. Vaccine. 2002; 20: S18-23.
8. Gupta RK. Aluminum compounds as vaccine adjuvants. Adv Drug Deliv Rev. 1998; 32: 155-72.
9. Lindbland EB. Aluminum compounds for use in vaccines. Immunol Cell Biol. 2004; 82: 497-505.
10. Safary A, Andre F. Over a decade of experience with a yeast recombinant hepatitis B vaccine. Vaccine. 1999; 18: 57-67.
11. Szmuness W, Stevens CE, Zang EA, Harley EJ, Kellner A. A controlled clinical trial of the efficacy of the hepatitis B vaccine (Heptavax B): a final report. Hepatology. 1981; 1: 377-385.
12. Hadler S, Francis DP, Maynard JE. Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men. N Engl J Med. 1986; 315: 209-14.
13. Ascherio A, Zhang SM, Hernan MA, Olek MJ, Coplan PM, Walker AM.. Hepatitis B vaccination and the risk of multiple sclerosis. N Engl J Med. 2001; 344: 327-32.
14. Confavreux C, Suissa A, Saddier P, Bourdes V, Vukusic S. Vaccinations and the risk of relapse of multiple sclerosis. Vaccines in Multiple Sclerosis Group. N Engl J Med. 2001; 344: 319-26.
15. Averhoff F, Mahoney F, Coleman P, Schatz G, Hurwitz E, Margolis H. Immunogenicity of hepatitis B vaccines: implications for persons at occupational risk of hepatitis B virus infection. Am J Prev Med. 1998; 15: 1-8.
16. West DJ, Calandra GB. Vaccine induced immunologic memory for hepatitis B surface antigen: implications for policy on booster vaccination. Vaccine. 1996; 14: 1019-27.
17. Halperin SC, Dobson S, McNeil S, Langley JM, Smith B, McCall-Sani R et al. Comparison of the safety and immunogenicity of hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide and a licensed hepatitis B vaccine in healthy young adults. Vaccine. 2006; 24: 20-6.
18. Ambrosch F, Wiedemann G, Kundi M, Leroux-Roels G, Desombere I, Garcon N et al. A hepatitis B vaccine formulated with a novel adjuvant system.. Vaccine. 2000; 18: 2095-101.
19. Immunological Products. British Pharmacopoeia, 2007. The Stationery Office, London, Appendix XIV.
20. Yuen MF, Lim WL, Cheng CC, Lam SK, Lai CL. Twelve-year follow-up of a prospective randomized trial of hepatitis B recombinant DNA yeast vaccine versus plasma-derived vaccine without booster doses in children. Hepatology. 1999; 29: 924-7.
21. Liao SS, Li RC, Li H, Yang JY, Zeng XJ, Gong J et al. Long-term efficacy of plasma-derived hepatitis B vaccine: a 15-year follow-up study among Chinese children. Vaccine. 1999; 17: 2661-6.
22. Williams IT, Goldstein ST, Tufa J, Tauillii S, Margolis HS, Mahoney F. Long term antibody response to hepatitis B vaccination beginning at birth and to subsequent booster vaccination. Ped Infect Dis J. 2003; 22: 157-63.
23. Ulanova M, Tarkowski A, Hahn-Zoric M, Hanson LA. The Common Vaccine Adjuvant Aluminum Hydroxide Up-Regulates Accessory Properties of Human Monocytes via an Interleukin-4-Dependent Mechanism. Infect Immun. 2001; 69: 1151-9.
24. Wang S, Liu X, Fisher K, Smith JG, Chen F, Tobery TW et al. Enhanced type I immune response to a hepatitis B DNA vaccine by formulation with calcium- or aluminum phosphate. Vaccine. 2000; 18: 1227-35.
25. Wang S, Liu X, Caulfield MJ. Adjuvant synergy in the response to hepatitis B vaccines. Vaccine. 2003; 21: 4297-306.
26. Brazolot Millan CL, Weeratna R, Krieg AM, Siegrist CA, Davis HL. CpG DNA can induce strong Thl humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice. Proc Natl Acad Sci. 1998; 95: 15553-8.
27. Shokrgozar MA, Shokri F. Subtype specificity of anti-HBs antibodies produced by human B-cell lines isolated from normal individuals vaccinated with recombinant hepatitis B vaccine. Vaccine. 2002; 20: 2215-20.